Sweet Syndrome Developed in a Patient of Acute Promyelocytic Leukemia During Remission Induction Therapy with All-trans Retinoic Acid.
- Author:
Sook Kyung LEE
1
;
Kee Won KIM
;
Suk Young PARK
Author Information
1. Division of Hematology-Oncology, Taejon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Acute Promyelocytic Leukemia;
Sweet Syndrome;
All-trans Retinoic Acid
- MeSH:
Humans;
Leukemia, Promyelocytic, Acute*;
Remission Induction*;
Sweet Syndrome*;
Tretinoin*
- From:Korean Journal of Hematology
1998;33(2):295-299
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
All-trans retinoic acid (RA) is recognized to be a drug of choice in remission induction of acute promyelocytic leukemia (APL), with some side effects including retinoic acid syndrome. But Sweet syndrome in association with RA is usually not serious nor well recognized. Early recognition of Sweet syndrome is important because additional therapy for this syndrome except steroid is not necessary. We report a case of Sweet syndrome developed in a patient of APL during remission induction therapy with RA.
